Kornimate/medical-research-clean huggingface dataset:
prevalence and risk factors of chronic thrombo-embolic disease after a pulmonary embolism event

Conditions: Chronic Emboilism

Summary: venous thromboembolic disease (vte) is a common clinical entity whose two manifestations are deep vein thrombosis (dvt) and pulmonary embolism (pe). after an acute pe, almost half of the patients complain residual dyspnea, despite well-conducted curative anticoagulation. some will present persistent defects on lung scan-scintigraphy, without pulmonary hypertension. this condition defines chronic-thrombo-embolic disease(cted). the prevalence of cted after pe is poorly known as are its risk factors. the primary objective is to determine the prevalence of cted at 3 or 6 months, depending on the provoked or unprovoked character, after a pe. the secondary objectives are: * to determine the potential risk factors for the occurrence of cted. * to look for an association between the persistence of dvt and the occurrence of cted. * to look for an association between the diagnosis of cted and pe recurrence during the 12-month follow-up. * to determine the diagnostic performance of the clinician alone compared to the lung scintigraphy (gold standard) for the diagnosis of cted. * to compare the impact on the quality of life (qol) with or without cted. * to determine the correlation between impaired qol and the degree of residual obstruction on lung scintigraphy.


Eligibility criteria:
inclusion criteria: * definite pe with expected life expectancy of more than 3 months - age ≥ 18 years old. * patients with a first episode of symptomatic pulmonary embolism, diagnosed by ct angiography or pulmonary scintigraphy and treated in a conventional manner. * having received oral information about the study and having expressed a non-opposition to participate to the study * benefiting from a social security scheme exclusion criteria: * patients with pulmonary hypertension. * patients who have already had a recurrence of pulmonary embolism or deep vein thrombosis of the lower limbs. * patients with a contraindication to performing a lung ventilation-perfusion scintigraphy. * patients at high risk of recurrence of venous thromboembolic disease (severe thrombophilia or active cancer). * classical contraindications to anticoagulants. * vulnerable patients: pregnant women, under guardianship or curatorship * premature termination of participation * recurrent pulmonary embolism diagnosed by ct angiography, or deep vein thrombosis diagnosed by venous doppler ultrasound of the lower limbs within the first 3 or 6 months depending on the nature of the vte. * occurence of pulmonary hypertension detected by trans-thoracic ultrasound (systolic pulmonary arterial pressure more than 35 mmgh).
a phase i open label study to assess pk and safety of plant cannabis extract

Conditions: Healthy

Summary: this study is an open-label, single-dose, healthy volunteer phase 1 study after overnight fasting designed to study the safety and pk of medicated drops and tablet formulation for sublingual administration.


Eligibility criteria:
inclusion criteria: 1. healthy, male or female, between 18 and 45 years of age (inclusive). 2. body mass index (bmi) between 20-30 kg/m2 (both inclusive) 3. no recent cannabis usage within 30 days from screening 4. normal rage hepatic functions 5. no electrolytes abnormalities 6. vital signs at screening (after five minutes resting measured in the supine position) within the following ranges: 1. body temperature between 35.0 to 37.5 °c 2. systolic blood pressure, 90 to 150 mmhg\* 3. diastolic blood pressure, 60 to 90 mmhg\* 4. pulse rate, 50 to 90 beats per minute\*. 5. \*blood pressure and pulse rate will be taken again in a standing position. after two minutes standing, there shall be no more than a 20 mmhg drop in systolic or 10 mmhg drop in diastolic blood pressure, associated with clinical manifestation of postural hypotension). exclusion criteria: 1. blood donation within 90 days 2. history of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastroenterology, endocrine, immunology, dermatologic, neurologic or psychiatric disorders 3. subjects with a history of alcohol, drug abuse, chronic cannabis use within 2 years of study 4. pregnant women 5. subjects who used any prescription or otc medication in the past 14 days with the exception of paracetamol or ibuprofen. 6. sexually active males whose partner is of childbearing potential who do not agree to practice two highly effective methods of birth control or remain abstinent during the study and for three months after the last dose of imp. sexually active females of childbearing potential who do not agree to practice two highly effective methods of birth control or remain abstinent during the study and for three months after the last dose of imp 7. pregnant, lactating or planning pregnancy during the course of the study and for three months thereafter. 8. subjects who had postural drop of \> 20 mmhg in systolic blood pressure at screening 9. patients with heart failure, 10. subjects with a history of psychotic state in the past or anxiety disorder, 11. subjects at age of less than 30 years with a history of psychiatric disease in a first-degree family member 12. subjects with a history of addiction or drug abuse
a diagnostic test on deepdoc-an ai-based decision support system

Conditions: Stroke; Headache; Vertigo; Meningitis/Encephalitis

Summary: deepdoc is an ai-based decision support system for the early etiology diagnosis of neurological diseases using clinical data points from patients admitted to hospital within 24 hours.this study aims to evaluate whether the diagnosis of the deepdoc ai-based decision support system is better than the doctor's initial diagnosis by a multi-center, superiority diagnostic study.

the doctor completes the admission note within 24 hours after the patient is admitted to the hospital. after informed consent is given to the patient who meet the inclusion criteria, open the deepdoc to fill in the patient identification information. then take the picture of the initial diagnosis of the admission note page and upload it to deepdoc, fill the doctor's initial diagnosis into the deppdoc. and put the patient's clinical data points into the deepdoc to get a deepddoc diagnosis.

Eligibility criteria:
inclusion criteria: 1. patients with clinical symptoms or signs suspected of stroke，meningitis/encephalitis, vertigo and headache. 2. neurological examination results and imaging changes within 24 hours of admission. exclusion criteria: patients discharged, transferred to the hospital, or died within 24 hours after admission.

Keywords: artificial intelligence
an open parallel study to determine the optimum dosing schedule for as-101 in aids/arc patients

Conditions: HIV Infections

Summary: to compare as-101 dosing schedules (once a week; 3 times a week; 5 times a week; or 5 times per week on alternate weeks) on the effect on clinical immunology and virus burden in aids or aids related complex (arc) patients.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * standard therapy for infections. * acyclovir. * ganciclovir. * allowed only with permission of wyeth-ayerst medical monitor: * zidovudine (azt). * immunomodulators. * specific therapy for malignancies (including kaposi's sarcoma). exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * evidence of severe liver dysfunction (serum albumin \ 5 x upper limit of normal, prothrombin time \> 15 seconds), or gastrointestinal, renal, respiratory, endocrine, hematologic, cardiovascular system abnormalities or psychiatric disorder other than abnormalities secondary to aids or aids related complex (arc). * evidence of aids-related central nervous system involvement. * disseminated kaposi's sarcoma. concurrent medication: excluded without permission of wyeth-ayerst medical monitor: * zidovudine (azt). * immunomodulators. * specific therapy for malignancies (including kaposi's sarcoma). patients with the following are excluded: * evidence of major system abnormalities other than abnormalities secondary to aids or aids related complex. * concomitant conditions as specified in patient exclusion co-existing conditions. * unlikely or unable to comply with the requirements of the protocol. prior medication: excluded within 4 weeks of study entry: * systemic antiviral agents. * immunosuppressive agents. * immune stimulators such as bcg vaccine, isoprinosine, or other immunomodulators. patients must: * have a diagnosis of aids or aids related complex (arc). * demonstrate intolerance or refusal to take zidovudine (azt). * provide written informed consent.

Keywords: drug therapy, combination acquired immunodeficiency syndrome aids-related complex ammonium trichloro(dioxoethylene-o,o'-)tellurute
yoga as a complementary therapy for adults with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this study will examine the feasibility and acceptability of a twice weekly yoga program for adults with type 2 diabetes. changes in perceived stress, salivary cortisol, and hba1c will also be examined.

the purpose of the current proposal is to test a yoga intervention for adults with t2dm and to gather data on the feasibility and acceptability of yoga compared to a contact control for glycemic control. the investigators will conduct a pilot randomized controlled study with participants randomly assigned to 1) yoga intervention, or 2) a standard exercise (se) group program (comparison-control). focus groups will be conducted with participants at the end of the intervention to identify facilitators and barriers to yoga practice and to examine their perceptions and beliefs about yoga and its relationship to stress and diabetes management. the investigators will explore the effect of yoga on stress (biomarker = salivary cortisol) that may act as a mechanism of action underlying the efficacy of yoga for improved glycemic control. the investigators will also measure hba1c levels, fasting and postprandial plasma glucose at baseline, end of treatment (12-weeks), 6- and 9-month follow-ups. study feasibility and acceptability will be assessed using participant recruitment, attendance and retention rates, and compliance with study protocols and satisfaction with the program. participants will also attend a focus-group discussion of the program at the end of treatment. results from this study will provide scientific basis for a future larger clinical trial. yoga, if found to offer advantages for glycemic control, can have potential for high impact on current practices of diabetes management.

Eligibility criteria:
inclusion criteria: * type 2 diabetes for more than 6 months * hba1c \> 6.5 * body mass index \< 42 exclusion criteria: * serious co-morbid condition (e.g. uncontrolled hypertension, glaucoma, heart failure) * complications of diabetes (e.g. diabetic retinopathy, neuropathy, nephropathy) * serious psychiatric disorder (e.g. psychosis, major depression, panic attacks, suicidality, or substance dependence) * body mass index of 42 or greater * pregnancy or planned pregnancy

Keywords: diabetes yoga walking stress exercise glycemic control
a phase ii trial to assess the effects of green tea in oral leukoplakia

Conditions: Oral Leukoplakia

Summary: you have been asked to participate in this research study because you have or may have oral leukoplakia. oral leukoplakia is described as a white patch or plaque on the oral mucosa (mouth) that will not rub off and cannot be removed by scraping, reversed by elimination of obvious irritants (things that cause redness and/or swelling) such as dentures (artificial replacment for missing teeth), or lesions as described that are diagnosed by your dentist.

since oral leukoplakia may precede the development of cancer, using agents that may prevent cancer, called chemoprevention, may be useful. the purpose of this study is to determine whether taking a green tea preparation may have effects on your leukoplakia. it is hoped that these effects may reduce the subsequent risk of cancer in or around the area of leukoplakia. to assess for these effects, samples of the lining of your mouth will be obtained, and they will be analyzed looking for certain features (biomarkers).

Eligibility criteria:
* patients with oral leukoplakia without evidence of active infections in the mouth will be invited to participate in this study. * patients must currently consume no more than 3 cups of tea a day, * not be taking large doses of vitamin a or its derivatives (more than 25,000 units), selenium, or beta-carotene. * additionally, patients must not participate in this study if they are allergic to caffeine, have gi ulcers, are pregnant, or have had previous invasive mouth cancer.

Keywords: oral leukoplakia
a dispensing clinical trial of comfilcon a extended range multifocal lenses

Conditions: Presbyopia

Summary: the aim of this study is to validate the clinical of comfilcon a extended range high add center near (cn) multifocal lenses in existing contact lens wearers against the current comfilcon a high add multifocal lenses.

this study is a 20-subject, randomized, prospective, single site, daily wear, single-masked (to the subject), bilateral, 4-day cross-over, dispensing study comparing the comfilcon a extended range multifocal test lens against the comfilcon a multifocal control lens.

Eligibility criteria:
inclusion criteria: a person is eligible for inclusion in the study if he/she: * has had a self-reported oculo-visual examination in the last two years * is 50 years of age or greater and has full legal capacity to volunteer * is able to read and understand the informed consent * is willing and able to follow instructions and maintain the appointment schedule * has a spherical distance contact lens prescription between -1.00 and -5.00d (diopters) (inclusive) * near add power requirement of +2.25d or greater * has spectacle cylinder 0.75 d in both eyes * has normal binocularity (no amblyopia, no strabismus, no habitually uncorrected anisometropia ≥ 2.00d) * has monocular best-corrected distance visual acuity of 20/30 or better in each eye * has clear corneas and no active ocular disease * has not worn gas permeable contact lenses for 1 month prior to the study exclusion criteria: a person will be excluded from the study if he/she: * has never worn contact lenses before * has any systemic disease affecting ocular health * is using any systemic or topical medications that will affect ocular health * has any ocular pathology or abnormality that would affect the wearing of contact lenses * is aphakic (i.e. missing their natural lens inside their eye) * has uncorrected anisometropia (i.e. difference in the prescription between the eyes) of ≥2.00 d * has undergone corneal refractive surgery * is participating in any other type of eye related clinical or research study.
prevalence of erythropoiesis stimulating agents hyporesponsiveness in dialysis patients in assiut university hospital

Conditions: Erythropoietin Resistant Anemia (EPO Resistant Anemia)

Summary: * the prevalence of erthropoietin stimulating agents hyporesponsiveness in hemodialysis patients in assiut university hospital * assessment of cardiovascular diseases risk in patients with erythropoiesis stimulating agents hyporesponsiveness in hemodialysis patients in assiut university hospital

anemia is common in patients with chronic kidney disease. the routine use of erthropoietin in anemia control has reduced morbidity and mortality rates in patients with chronic kidney disease. despite an increase in the use and average dose of recombinant human epoetin over the last 15 years, a substantial percentage of patients still don't achieve hemoglobin targets recommend by international guidelines. the definition of recombinant human epoetin resistance has been introduced to identify those patients in whom the target hemoglobin level is not attained despite a greater than usual dose of erthropoietin stimulating agent. in recent years, increasing attention has been paid to the relationship between dialysis, increased inflammatory stimulus, malnutrition, and erythropoiesis stimulating agents response. erythropoiesis stimulating agents hyporesponsiveness was defined by the erythropoietin resistance index, which was the erythropoietin dose per week divided by body weight and hemoglobin level . the resistance to erythropoiesis stimulating agents is directly related with incident comorbidity in patients on hemodialysis and it can be interpreted as a useful marker of early mortality. patients with higher erythropoietin resistance index values had a higher all cause mortality rate and cardiovascular mortality rate. erythropoietin resistance index was related with left ventricular mass index, left ventricle systolic function and cardiovascular events in patients with hemodialysis. by monitoring of erthropoietin resistance index, early identification of the epoetin resistance may be useful to predict the cardiovascular risk in hemodialysis patients

Eligibility criteria:
inclusion criteria: * age more than 18 * end stage renal disease patients undergoing regular hemodialysis in assiut university hospital - hemodialysis unit for duration at least 3 months exclusion criteria: * acute infectious disease within one month * active liver disease or cancer * recent blood transfusion or surgical intervention * active bleeding or hemorrhage
progressive splinting status post elbow fractures and dislocations

Conditions: Upper Extremity Fracture; Upper Extremity Dislocation; Fractures, Comminuted; Elbow Fracture; Elbow Dislocation

Summary: the purpose of this study is to help determine if a static stretching brace in addition to physical therapy decreases the incidence of secondary operations, increases range of motion, and individual patient function.

fractures and dislocations about the elbow are high energy injuries which are often comminuted and associated with extensive soft tissue damage and are very difficult to treat. the most problematic complication for these fractures is the potential development of a cosmetic defect and functional disability due to the loss of 20 degrees to 30 degrees of terminal extension of the elbow. it has been found imperative that early motion and physical therapy be implemented to help produce the best results in terms of a patient's range of motion and decreases secondary surgeries. we intend to examine a group of patients with distal humerus and elbow fracture/dislocations who use static stretching braces along with physical therapy (pt) within 3 weeks after surgery, in contrast to physical therapy treatment alone after surgery. the static stretching brace group will have a small electronic circuit attached to the brace that will record patient's usage. improvement of patient's overall functional outcome will also be measured by a standard functional outcome instrument, the disabilities of arm, shoulder and hand (dash) form. the dash form is a standard functional outcome instrument specific to upper extremity injuries. in addition, a more general measure, the visual analog scale (vas), will be used to assess pain. the use of the static motion brace may help eliminate the necessity of additional treatments, saving both pain and suffering, as well as monetary costs for the patient, while simultaneously producing a better long term functional and cosmetic outcome.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * extra or intraarticular distal humerus or elbow fracture or fracture/dislocation * agrees to participate and signs informed consent * english speaking (outcome questionnaires are validated for english only) exclusion criteria: * less than 18 years of age * closed head injury * burn injuries * ipsilateral upper extremity fracture(s) requiring surgery * nonunion of prior distal humerus fracture or fracture dislocation * type 3 open distal humerus fracture dislocation * insufficient fracture fixation to allow early range of motion * transient population with no fixed address * not willing to sign informed consent * does not speak english

Keywords: elbow upper extremity fractures distal humerus elbow injuries dislocations peri-articular elbow injuries
vitamin e level in buccal cells of arsenicosis patients

Conditions: Chronic Arsenic Poisoning

Summary: to understand the pathogenesis of chronic arsenic toxicity, the investigators need to know the levels of vitamin e in patients chronically exposed to high concentration of arsenic and if changes are found, what happens when supplemented with vitamin e. the buccal cells and serum of patients will be collected for the estimation of vitamin e both before and after supplementation with vitamin e. similar samples will be collected from similar number of arsenic exposed controls and healthy volunteers for comparison.

chronic consumption of arsenic through water (drinking and cooking) and food leads to accumulation of arsenic within the cell. we usually give emphasis on the skin manifestations (melanosis and keratosis) of arsenicosis that is diagnosed first. other manifestations remain un-diagnosed or diagnosed later. the severe form is the development of cancer in different organs mainly skin, lungs and urinary bladder. to understand the pathophysiology of the development of clinical manifestations appearing in the skin first, we need to understand interior of cells other than skin. one of the dietary supplements, vitamin e is found to be effective in improving the clinical signs/symptoms of melanosis and keratosis. buccal cells are also exposed to arsenic and easy to collect. to understand the pathogenesis, we need to know the levels of vitamin e in patients of arsenicosis and if changes, what happens when supplemented with vitamin e. the buccal cells and serum of 20 patients will be collected for the estimation of vitamin e both before and after supplementation with vitamin e (200 iu, caplet) daily orally for 20 weeks. similar samples will be collected from 20 arsenic exposed controls and 20 healthy volunteers for comparison.

Eligibility criteria:
inclusion criteria: for arsenicosis * who drank arsenic contaminated water (\>50 µg/l) for more than 6 months * having physical signs of moderate degree of melanosis and keratosis for arsenic exposed control * relative or family member of the patient * showing no physical signs of melanosis and keratosis * share same tube well water for drinking purpose for more than 6 months for healthy volunteers * who drank arsenic safe water (\<50 µg/l) * live in the same upazilla * have no cutaneous manifestation * who voluntarily agree to participate exclusion criteria: * tuberculosis, eczema psoriasis, contact dermatitis * patients getting treatment of arsenicosis * subject who voluntarily do not agree to participate

Keywords: arsenic arsenicosis buccal cells serum vitamin e cholesterol
quantifying the deterioration of physical function in renal patients

Conditions: End Stage Renal Disease

Summary: patients undergoing haemodialysis present a decrease in physical function, but little is known about the rate at which function decreases. the purpose of this study is quantifying the nature and degree of functional deterioration experienced by stage 5 chronic kidney disease patients during a six month period of maintenance haemodialysis therapy.


Eligibility criteria:
inclusion criteria: * people under hemodialysis treatment at least 3 months * be medicable stable * complete all the physical tests exclusion criteria: * heart stroke in the previous 6 weeks of the study * inferior limb amputation without artificial aids * cerebral vascular disease (ictus, ischemic) * disability to complete functional tests